

CLINICAL



TRIALS



COURSE

SATURDAY, SEPTEMBER 13, 2025
8:00 AM – 3:15 PM
BALTIMORE, MD



The ANA Clinical Trials Course is designed to further the career development of academic neurologists and neuroscientists interested in conducting clinical research.

Compared to fields such as oncology and cardiology, the clinical neurosciences often lack well established pathways for providing this kind of training for emerging clinician-scientists. This day-long course will engage academic neurologists and neuroscientists in an analysis of the clinical development and testing of therapies for neurological diseases.

Most participants will not have yet developed long-term clinical research programs or funding, but they will have intentions to work in this area.

Throughout the course, strategies for career development will be interwoven with the didactic material, and the day will include time for networking with other participants and speakers.



Course Schedule

8:00 AM – 8:15 AM

Introduction

Chair: Craig Blackstone, MD, PhD, FANA | Massachusetts General Hospital

8:15 AM – 9:00 AM

Producing Neurologic Therapies: Present and Future

Speaker: Walter Koroshetz, MD, FANA | National Institute of Neurological Disorders and Stroke; National Institutes of Health

9:00 AM – 9:30 AM

Intro to Clinical Study Design

Speaker: Pooja Khatri, MD, MSc | Yale University

9:30 AM – 10:00 AM

How to Do Translational Neurology in Academia

Speaker: Kevin Sheth, MD, FANA | Yale School of Medicine

10:00 AM – 10:30 AM Break

10:30 AM – 11:00 AM

Development of Targeted Therapies for Parkinson's Disease

Speaker: Dimitri Krainc, MD, PhD, FANA | Northwestern University

11:00 AM – 11:30 AM

How to Get (and Stay) Funded

Speaker: Justin McArthur, MBBS, MPH, FAAN, FANA | Johns Hopkins School of Medicine

11:30 AM – 12:00 PM

New Approaches to Clinical Trials

Speaker: Sabrina Paganoni, MD, PhD | Massachusetts General Hospital

12:00 PM – 1:00 PM Lunch

1:00 PM – 1:30 PM

Starting and Developing a Successful Career as a Clinical Trialist

Speaker: Amanda Guidon, MD, MPH | Massachusetts General Hospital

1:30 PM – 2:00 PM

Accelerating Clinical Research with Internet Recruitment and Direct To Participant Trials

Speaker: Caroline Tanner, MD, PhD, FANA | University of California, San Francisco

2:00 PM – 2:15 PM Break

2:15 PM – 2:45 PM

Using the CTSA System Effectively

Speaker: Anthony Kim, MD, MAS | University of California, San Francisco

2:45 PM – 3:15 PM

The Role of Industry in Clinical Trials

Speaker: Ludy Shih, MD, MMSc, FANA | Beth Israel Deaconess Medical Center

Adjourn



Meet Our Speakers



Chair

Craig Blackstone, MD, PhD, FANA **Massachusetts General Hospital**

Dr. Craig Blackstone is Vice Chair for Research and Division Chief of Movement Disorders in the Department of Neurology at Massachusetts General Hospital, and Professor of Neurology at Harvard Medical School.

Previously, he was a Senior Investigator in the Intramural Research Program of the National Institute of Neurological Disorders and Stroke. His research group investigates the cellular and molecular mechanisms underlying inherited movement disorders. He is an elected member of the American Society for Clinical Investigation, the Association of American Physicians, and the National Academy of Medicine, as well as an elected Fellow and former Vice President of the American Neurological Association.

Amanda Guidon, MD, MPH **Massachusetts General Hospital**

Dr. Amanda Guidon is Neuromuscular Disorders Division Chief at Mass General Brigham and Assistant Professor of Neurology at Harvard Medical School. She cares for patients with myasthenia gravis (MG) and with neuromuscular immune related adverse events of cancer immunotherapy. She designs and conducts clinical trials in MG, and her research is focused on improving healthcare delivery and outcomes via novel outcome measures, including remote monitoring tools. Dr. Guidon co-edited the new edition of Amato and Russell's Neuromuscular Medicine Textbook and has co-authored chapters on MG for upcoming editions of Harrison's Principles of Internal Medicine and Bradley's Neurology in Clinical Practice.



Pooja Khatri, MD, MSc **Yale University**

Dr. Pooja Khatri is a Professor at Albert E. Kent Professor and Chair of Neurology at Yale University. She co-directs the National Coordinating Center of NIH StrokeNet, the primary infrastructure for developing and implementing multicenter trials of stroke funded by NIH and training the next generation. With 20 years of sustained NIH funding, in addition to industry funding, she has broad experience in therapeutic development from conception to post-marketing phases including translational, study design, regulatory, safety, and ethical aspects. Her scientific expertise and contributions span acute stroke therapy, prevention of early stroke recurrence, biomarkers of stroke recovery, and population-level epidemiology of stroke and brain health.





Anthony Kim, MD, MAS
University of California, San Francisco

Dr. Anthony Kim is a Professor of Clinical Neurology at the University of California, San Francisco (UCSF) where he is the Erich Fried Endowed Professor of Vascular Neuroscience. He leads quality improvement and clinical innovation efforts as medical director of the UCSF Comprehensive Stroke Center and directs the Consultation Services program at the UCSF Clinical and Translational Science Institute which provides biostatistics and study design consultations for investigators across the campus. His research is focused on addressing key challenges in the development, evaluation, dissemination, and implementation of interventions to reduce the burden of cerebrovascular disease.



Walter Koroshetz, MD, FANA
National Institute of Neurological Disorders and Stroke (NINDS)

Dr. Walter Koroshetz is the Director of the National Institute of Neurological Disorders and Stroke (NINDS). He works to advance the mission of the Institute, to improve fundamental knowledge about the brain and the nervous system, and to use that knowledge to reduce the burden of neurological disorders. He joined NINDS as the Deputy Director in 2007. Before coming to NIH, Dr. Koroshetz was a Harvard Professor of Neurology, Vice Chair of Neurology at the Massachusetts General Hospital, director of Stroke and Neurointensive Care, and a member of the MGH Movement Disorders clinic. His research activities spanned basic neurobiology to clinical trials. He directed Neurology training at MGH for 16 years. A graduate of Georgetown University and University of Chicago Medical School, Dr. Koroshetz specialized in Internal Medicine and Neurology.



Dimitri Krainc, MD, PhD, FANA
Northwestern University

Dr. Dimitri Krainc is the Ward Professor and Chairman of the Department of Neurology and Director of the Feinberg Neuroscience Institute at Northwestern. Previously, Krainc spent two decades at the Massachusetts General Hospital and Harvard Medical School, where he completed his research and clinical training and served on faculty. His research group has uncovered key mechanisms of neurodegeneration that have led to the development of targeted therapies. Krainc received the Javits Neuroscience Investigator Award, Outstanding Investigator award from NIH, and was elected to the Association of American Physicians, National Academy of Medicine, and the National Academy of Inventors. He serves as President-elect of the American Neurological Association.





Justin McArthur, MBBS, MPH, FAAN, FANA
Johns Hopkins School of Medicine



Dr. Justin McArthur is nationally and internationally recognized for his work in studying the natural history, development and treatment of HIV infection, multiple sclerosis and other neurological infections and immune-mediated neurological disorders. He developed a technique to use cutaneous nerves to study sensory neuropathies, including those associated with chemotherapy, HIV and diabetes, which has been incorporated into clinical practice on a world-wide basis. He is the founding director of the Johns Hopkins/National Institute of Mental Health Research Center for Novel Therapeutics of HIV-associated Cognitive Disorders. Dr. McArthur is the current Director of the Johns Hopkins Department of Neurology and holds the John W. Griffin Professorship in neurology. He is a Professor of Neurology, Epidemiology, Medicine and Pathology at the Johns Hopkins School of Medicine and the Neurologist-in-Chief of the Johns Hopkins Hospital.

Sabrina Paganoni, MD, PhD
Massachusetts General Hospital

Dr. Sabrina Paganoni is an Associate Professor of PM&R at Harvard Medical School/Spaulding Rehabilitation Hospital. She is also the Co-Director of the Neurological Research Institute at the Massachusetts General Hospital and physician scientist at the Healey & AMG Center for ALS. Her research focuses on clinical trials and therapy development for ALS. She is the Principal Investigator of several ALS clinical trials and has pioneered novel trial designs and partnership models to innovate the way investigational products are tested in ALS. She is the co-PI of the HEALEY ALS Platform Trial, the first platform trial for ALS in the world and is leading multi-center expanded access programs. Her research has been funded by the NIH, non-profits, and industry; she published more than 160 peer-reviewed manuscripts and received several awards for her work including the 2021 Top 10 Clinical Research Achievement Award.



Kevin Sheth, MD, FANA
Yale School of Medicine



Dr. Kevin Sheth is the Vice Chair for Clinical & Translational Research in Neurology & Neurosurgery and a founding Director of the Yale Center for Brain & Mind Health. He is recognized for his leadership in prevention, acute treatment, and recovery stroke research and has led and developed highly innovative programs in drug development, translation, and medical devices. He has served as PI or co-PI for eight multicenter clinical trials in stroke and chaired clinical endpoint and data safety monitoring committees. He is a winner of the Robert Siekert Award from the American Heart Association, the Derek Denny Brown Award from the American Neurological Association, and an elected member of the American Society for Clinical Investigation. Dr. Sheth holds several patents and is a co-founder for early-stage companies, including efforts that led to the successful translation of glyburide to multiple phase II studies and FDA clearance for the world's first clinically relevant portable MRI system.



Ludy Shih, MD,MMSc, FANA
Beth Israel Deaconess Medical Center

Dr. Ludy Shih received her MD from the University of California Los Angeles and completed internship, neurology residency, and movement disorders fellowship at Harvard Medical School/Beth Israel Deaconess Medical Center (BIDMC), with a master's in clinical investigation through the Harvard-MIT Health Sciences and Technology Clinical Investigator Training Program. She is a clinical investigator in Parkinson's disease (PD) and essential tremor and worked at Biogen and Vertex Pharmaceuticals, designing global phase 1/2 clinical studies for PD and genetic neurologic diseases. She is Associate Editor at *Annals of Clinical and Translational Neurology* and President and Co-Chair of the Scientific Program Committee for the American Society of Experimental Neurotherapeutics.



Caroline Tanner, MD, PhD, FANA
University of California, San Francisco

Dr. Caroline Tanner specializes in movement disorders. Her research includes descriptive epidemiology, environmental and genetic determinants, biomarkers, early detection, nonmotor features and clinical trials. She is co-PI of the home-based TOPAZ fracture prevention study for people with neurodegenerative parkinsonism and the hybrid Micro-PD trial to reduce off periods in people with Parkinson's disease. She is a member of the Parkinson's Progression Markers Initiative leadership team and PI of PPMI Online, FOUND-PPMI and the online Fox Insight study. She has been fortunate to mentor talented students from many countries, who themselves are now leading researchers and educators worldwide.





Mission

Advancing science, education, and careers to improve neurologic health for all.

Vision

A world without neurological disease.